Related Experiment Video
Updated: Jan 22, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
Published on: January 28, 2014
Effectiveness of Statins as Primary Prevention in People With Gout: A Population-Based Cohort Study
Maria Garcia-Gil1,2, Marc Comas-Cufí1,2, Rafel Ramos1,2,3,4
11 Institut Universitari d'Investigació en Atenció Primària Jordi Gol ( IDIAJGol), Catalonia, Spain.
Insights
Statin therapy did not significantly reduce coronary heart disease (CHD) in patients with gout. Cardiovascular risk assessment and patient preferences should guide treatment decisions for gout patients in primary prevention.
Area of Science:
- Cardiology
- Rheumatology
- Pharmacology
Background:
- Cardiovascular disease (CVD) risk is elevated in patients with gout.
- Current cardiovascular guidelines lack specific recommendations for statin use in gout patients due to insufficient evidence.
Purpose of the Study:
- To evaluate the effectiveness of statin therapy in the primary prevention of coronary heart disease (CHD), ischemic stroke (IS), and all-cause mortality among individuals with gout.
Main Methods:
- Retrospective cohort study using electronic medical records from July 2006 to December 2017.
- Included primary care patients aged 35-85 without prior CVD, comparing new statin users with non-users.
- Propensity score-adjusted Cox proportional hazards modeling was used to analyze outcomes.
Main Results:
- Statin therapy showed no significant reduction in the incidence of CHD (HR 0.84, 95% CI: 0.60-1.19).
- No significant reduction was observed for ischemic stroke (HR 0.68, 95% CI: 0.44-1.05) or all-cause mortality (HR 0.87, 95% CI: 0.67-1.12).
- A potential increased hazard for diabetes was noted (HR 1.27, 95% CI: 0.99-1.63).
Conclusions:
- Statin therapy was not associated with a clinically significant decrease in CHD incidence in this gout population.
- Treatment decisions for gout patients in primary prevention should consider individual cardiovascular risk, lifestyle, and patient preferences, aligning with current rheumatology recommendations.
Background:
Cardiovascular guidelines do not give firm recommendations on statin therapy in patients with gout because evidence is lacking.
Aim:
To analyze the effectiveness of statin therapy in primary prevention of coronary heart disease (CHD), ischemic stroke (IS), and all-cause mortality in a population with gout.
Methods:
A retrospective cohort study (July 2006 to December 2017) based on Information System for the Development of Research in Primary Care (SIDIAPQ), a research-quality database of electronic medical records, included primary care patients (aged 35-85 years) without previous cardiovascular disease (CVD). Participants were categorized as nonusers or new users of statins (defined as receiving statins for the first time during the study period). Index date was first statin invoicing for new users and randomly assigned to nonusers. The groups were compared for the incidence of CHD, IS, and all-cause mortality, using Cox proportional hazards modeling adjusted for propensity score.
Results:
Between July 2006 and December 2008, 8018 individuals were included; 736 (9.1%) were new users of statins. Median follow-up was 9.8 years. Crude incidence of CHD was 8.16 (95% confidence interval [CI]: 6.25-10.65) and 6.56 (95% CI: 5.85-7.36) events per 1000 person-years in new users and nonusers, respectively. Hazard ratios were 0.84 (95% CI: 0.60-1.19) for CHD, 0.68 (0.44-1.05) for IS, and 0.87 (0.67-1.12) for all-cause mortality. Hazard for diabetes was 1.27 (0.99-1.63).
Conclusions:
Statin therapy was not associated with a clinically significant decrease in CHD. Despite higher risk of CVD in gout populations compared to general population, patients with gout from a primary prevention population with a low-to-intermediate incidence of CHD should be evaluated according to their cardiovascular risk assessment, lifestyle recommendations, and preferences, in line with recent European League Against Rheumatism recommendations.
Related Concept Videos
Conservation of Small Populations
What is Population Genetics?
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Population Growth
Framing Effects

